GlassScriptPhysician profile
Supriya Thirunarayanan
NPI 1548324163
$9,664.13
in general payments reported to CMS, 2019-2025
49 companies · $2,308 in 2025
The $2,308 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.02 · 2020: $263 · 2021: $304 · 2022: $1,445 · 2023: $3,548 · 2024: $1,754 · 2025: $2,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,557 · Travel and Lodging: $949 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,557.36 |
| Travel and Lodging | $948.54 |
| Education | $104.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,566.48 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,422.04 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Sk Life Science, INC. | $991.46 | 2020-2025 | Xcopri |
| Sumitomo Pharma America, INC. | $497.81 | 2023-2024 | Aptiom |
| Ucb, INC. | $433.03 | 2022-2025 | Briviact, Rystiggo, Fintepla |
| Lundbeck LLC | $427.15 | 2020-2025 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $382.99 | 2022-2024 | Austedo Xr, Austedo |
| Pfizer INC. | $342.12 | 2023-2025 | |
| Genentech USA, INC. | $319.18 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Biogen, INC. | $258.09 | 2021-2025 | Vumerity, Skyclarys, Tysabri |
| Argenx US, INC. | $233.40 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $195.66 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Neurocrine Biosciences, INC. | $167.67 | 2022-2023 | Ingrezza, Ongentys |
| Celgene Corporation | $165.83 | 2022-2024 | Zeposia |
| Merz Pharmaceuticals, LLC | $165.29 | 2024-2025 | Xeomin |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Thirunarayanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.